Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ADI-001

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Adicet Bio

Drug class:

γδ TCR modulator, CD20-targeted CAR-T immunotherapy

Related drugs:

‹

multi-CAR-T cell therapy (0)

sequential different B cell antigen-targeted CAR T-cell therapy (0)

MB-CART2019.1 (0)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

BTN2A1/3A1-Fc-CD19scFv (0)

CD7-UCAR-γδT cells (0)

ET1402L1-ARTEMIS T cells (0)

Gamma delta T-cells (0)

autologous γδ T lymphocytes (0)

ALEXIS-ISO-1 (0)

NK/γδ T cell-enriched cell therapy (0)

PF-08046052 (0)

anti-CD19-CAR γδT (0)

γδT Cell infusion (0)

γδT Cell infusion agent (0)

4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)

Anti-CD19/CD20/CD22 CAR T-Cells (0)

CAR-20/19-T Cells (0)

CAR-T CD19/CD20/CD22/CD30 (0)

CAR20.19.22 T (0)

CD19/CD20 CAR T-cells (0)

CD20-CD19 cCAR T cells (0)

JNJ-90009530 (0)

MB-CART20.1 (0)

P-CD19CD20-ALLO1 (0)

autologous TriCAR T (0)

multi-CAR-T cell therapy (0)

sequential different B cell antigen-targeted CAR T-cell therapy (0)

MB-CART2019.1 (0)

›

CD20 expression

Sensitive: C3 – Early Trials

Sensitive: C3 – Early Trials